Mar 17 2010
CDI Corp. (NYSE: CDI) today announced that its CDI Engineering Solutions division has entered into an alliance partnership with MaisonWorleyParsons, the largest international E&C contractor in China, to provide engineering design and Engineering, Procurement & Construction Management (EPCM) services for pharmaceutical and biotechnology manufacturing facilities in China.
The alliance with MaisonWorleyParsons will allow CDI to apply its engineering, commissioning and validation experience to the development of pharmaceutical and biotechnology manufacturing and R&D facilities in China. It also provides MaisonWorleyParsons the ability to offer its extensive client base additional services in conjunction with its current chemical, oil/gas, power and infrastructure capabilities.
"Our CDI-Life Sciences group has a great deal of experience developing pharmaceutical and biotech designs that meet US FDA engineering and construction guidelines," said Robert Giorgio, President of CDI Engineering Solutions. "We look forward to applying this knowledge as we work with MaisonWorleyParsons on key manufacturing facilities in China."
"By leveraging MaisonWorleyParsons' five design offices in China, CDI can now offer our high-value engineering services to a broader range of clients," added Ronald Friedman, Vice President of Global Project Development & Technology for CDI-Life Sciences.
"We are confident the joint team of CDI's design expertise and MaisonWorleyParsons vast China capability and experience will prove to be a great asset as we continue to develop world-class life science facilities," said Mike Silva, CEO of MaisonWorleyParsons.
"Additionally," said Karl Qiu, President of MaisonWorleyParsons, "our geographic reach and broad experience in China along with our bilingual capabilities will contribute to the successful creation of next generation manufacturing and R&D facilities."
Source: http://www.cdi-ls.com